Tenax Therapeutics shareholders approve officer exculpation, reject meeting-vote mandate

TENAX THERAPEUTICS, INC.

Shareholders approved officer exculpation amendment (2,458,203 for, 10,244 against); effective upon filing.
All seven director nominees elected; June Almenoff received 2,460,500 votes in favor.
Proposal requiring all stockholder action at meetings rejected (1,915,960 for, 563,768 against).
Non-binding say-on-pay approved (2,435,043 for); advisory vote to occur every two years.
Cherry Bekaert LLP ratified as auditor for FY2025 (2,976,524 for).

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.